401 related articles for article (PubMed ID: 15060573)
21. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
Altenschmidt U; Kahl R; Moritz D; Schnierle BS; Gerstmayer B; Wels W; Groner B
Clin Cancer Res; 1996 Jun; 2(6):1001-8. PubMed ID: 9816261
[TBL] [Abstract][Full Text] [Related]
22. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
[TBL] [Abstract][Full Text] [Related]
23. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
24. Adoptive antitumor immunotherapy in vitro and in vivo using genetically activated erbB2-specific T cells.
Wang C; Hu W; Shen L; Dou R; Zhao S; Shan D; Yu K; Huang R; Li H
J Immunother; 2014 Sep; 37(7):351-9. PubMed ID: 25075564
[TBL] [Abstract][Full Text] [Related]
25. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
26. Tumor ablation by gene-modified T cells in the absence of autoimmunity.
Wang LX; Westwood JA; Moeller M; Duong CP; Wei WZ; Malaterre J; Trapani JA; Neeson P; Smyth MJ; Kershaw MH; Darcy PK
Cancer Res; 2010 Dec; 70(23):9591-8. PubMed ID: 21098715
[TBL] [Abstract][Full Text] [Related]
27. [Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].
Li SP; Urban FA; Macgregor JN; Hughes DP; McDonagh KT
Ai Zheng; 2004 Nov; 23(11 Suppl):1370-5. PubMed ID: 15566639
[TBL] [Abstract][Full Text] [Related]
28. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
29. The role of CD28 costimulation in immune-mediated responses against mouse mammary tumor viruses.
Palmer LD; Saha B; Hodes RJ; Abe R
J Immunol; 1996 Mar; 156(6):2112-8. PubMed ID: 8690899
[TBL] [Abstract][Full Text] [Related]
30. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains.
Roberts MR; Cooke KS; Tran AC; Smith KA; Lin WY; Wang M; Dull TJ; Farson D; Zsebo KM; Finer MH
J Immunol; 1998 Jul; 161(1):375-84. PubMed ID: 9647246
[TBL] [Abstract][Full Text] [Related]
31. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
Chmielewski M; Hombach AA; Abken H
Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
[TBL] [Abstract][Full Text] [Related]
32. CD2-mediated signaling in T cells lacking the zeta-chain-specific immune receptor tyrosine-based activation (ITAM) motif.
Steeg C; von Bonin A; Mittrücker HW; Malissen B; Fleischer B
Eur J Immunol; 1997 Sep; 27(9):2233-8. PubMed ID: 9341764
[TBL] [Abstract][Full Text] [Related]
33. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
[TBL] [Abstract][Full Text] [Related]
34. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
35. The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes.
Geiger TL; Leitenberg D; Flavell RA
J Immunol; 1999 May; 162(10):5931-9. PubMed ID: 10229830
[TBL] [Abstract][Full Text] [Related]
36. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
Rohrbach F; Gerstmayer B; Biburger M; Wels W
Clin Cancer Res; 2000 Nov; 6(11):4314-22. PubMed ID: 11106249
[TBL] [Abstract][Full Text] [Related]
37. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.
Turatti F; Figini M; Balladore E; Alberti P; Casalini P; Marks JD; Canevari S; Mezzanzanica D
J Immunother; 2007 Oct; 30(7):684-93. PubMed ID: 17893561
[TBL] [Abstract][Full Text] [Related]
38. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
Blanco B; Holliger P; Alvarez-Vallina L
Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
[TBL] [Abstract][Full Text] [Related]
39. Monovalent antibody scFv fragments selected to modulate T-cell activation by inhibition of CD86-CD28 interaction.
Kolly R; Thiel MA; Herrmann T; Plückthun A
Protein Eng Des Sel; 2007 Feb; 20(2):91-8. PubMed ID: 17289805
[TBL] [Abstract][Full Text] [Related]
40. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
